ERBB2 and ovarian cancer: Currently, many glycosylated proteins are approved to be clinical biomarkers, e.g., prostate-specific antigen (PSA) in prostate cancer, cancer antigen (CA) 125 in ovarian cancer, α-fetoprotein (AFP) in HCC, and HER2/neu in breast cancer.